Eli Lilly’s existing non-binding Technology Evaluation Agreement with Peptron, extended through October 7, 2026, remains limited to joint in-vivo research applying SmartDepot microsphere technology to Lilly’s peptide candidates, including GLP-1 agents for obesity and expanded CNS indications. This stage grants only a non-exclusive internal R&D license and explicitly excludes commercial rights, with termination possible on 30 days’ notice. No official announcements, technology transfer filings, or credible reports indicate a shift to a binding commercial licensing or tech-transfer deal has occurred, while Lilly continues exploring alternative sustained-release platforms such as Camurus’ FluidCrystal. Ongoing validation studies and Peptron’s own pipeline progress (PT403/PT404) have not yet produced the definitive data or negotiations needed for immediate commercialization. A last-minute announcement remains possible but faces significant procedural and evidentiary hurdles in the final 48 hours.